
News|Articles|June 1, 2010
FDA Pipeline Preview, June 2010 (BMS-224818, Roflumilast, Prostvac, Naltrexone, IL13-PE38QQR/IL13-PE, Prochymal, AEZS-108, SBC-102, Pralatrexate, RG2833)
Recent FDA action (through, May 2010) related to BMS-224818, Roflumilast, Prostvac, Naltrexone, IL13-PE38QQR/IL13-PE, Prochymal, AEZS-108, SBC-102, Pralatrexate, RG2833
Advertisement
Complete reponse
Fast-track designation
Priority review
Newsletter
Get the latest industry news, event updates, and more from Managed healthcare Executive.
Advertisement
Advertisement
Advertisement
Trending on Managed Healthcare Executive
1
The FDA proposes ditching comparative efficacy studies for biosimilars
2
How new psoriasis, alopecia and atopic dermatitis therapies stood out at Fall Clinical Derm 2025
3
Misdiagnosis of Type 1 diabetes remains a major problem, despite advances
4
Winter exposes how closely eczema, asthma and allergies are linked
5

















































